Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

GH Secretagogue Stack

GH Stack · CJC-1295 + Ipamorelin Stack · CJC/Ipamorelin Stack

Animal replicated

Research chemicalGH Secretagogue Stack GHRH Analog GHRP Peptide Stack

RouteInjectableGray-market only

Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance

What it is: CJC-1295 + Ipamorelin — GHRH/GHRP Growth Hormone Secretagogue Stack — GH Secretagogue Stack, GHRH Analog, GHRP, Peptide Stack.
Why people use it: Used primarily for muscle and performance and sleep and recovery.
What the evidence supports: IGF-1 (insulin-like growth factor 1) is the primary downstream marker of GH axis activity. It is the only practical way to verify the GH Stack is producing meaningful GH elevation and to identify over-elevation risk.

If you only read one thing

The GH Stack has better mechanistic and clinical supporting evidence than any other stack in this reference. The GHRH+GHRP synergy is replicated across species, multiple compound pairs, and over 30 years of research. CJC-1295 has Phase 1/2 human trial data (Teichman 2006: IGF-1 elevation +35-120% dose-dependent). Ipamorelin's selectivity advantage (no cortisol, no prolactin, no ACTH) was demonstrated in human pharmacology by Raun et al. (1998). The central tension is not evidence quality — it is the DAC distinction. A significant portion of community users receive or purchase CJC-1295 WITH DAC believing it is equivalent to CJC-1295 without DAC. It is not. DAC fundamentally changes the pharmacology from pulsatile to sustained — producing receptor desensitization and blunting natural GH pulsatility rather than enhancing it. Getting the DAC question right is the most important practical element of this chapter.

Check interactions →

Published literature

0human trials0human studies0animal0in vitro

Evidence reality check

Human evidence

No human studies

0 observational; RCT evidence not present in corpus.

Preclinical base

0 lab signals

0 animal; 0 in-vitro/mechanistic.

Evidence snapshot

IGF-1 (insulin-like growth factor 1) is the primary downstream marker of GH axis activity. It is the only practical way to verify the GH Stack is producing meaningful GH elevation and to identify over-elevation risk.

From the chapter quick-reference block.

Categories

Muscle & Performance Sleep & Recovery

Properties

Not injectable

Half-life

Without the DAC (Drug Affinity Complex) modification, it has a plasma half-life of approximately 30 minutes — comparable to natural GHRH

Evidence

CAnimal replicated

Stack Type

GH secretagogue combination. Not FDA-approved for these indications. Research protocol. Type: stack. Slug: gh-stack. stackGrade: B (GHRH+GHRP synergy is well-established in clinical research; specific CJC-1295 no-DAC + Ipamorelin combination has strong supporting evidence). Components: cjc-1295-no-dac, ipamorelin. Related stacks: metabolic-stack.

Stack Indication

Growth hormone optimization: improved sleep quality (SWS enhancement), body composition (fat loss, lean mass support), recovery acceleration, anti-aging GH axis support. Not a substitute for diagnosed GH deficiency treatment with pharmaceutical HGH.

The Two Mechanisms

CJC-1295 (no DAC) = Modified GRF 1-29; GHRH analog; activates GHRH receptor on pituitary somatotrophs; amplifies GH pulse amplitude; half-life ~30 min (injectable pulse). Ipamorelin = selective ghrelin receptor agonist (GHS-R1a); triggers clean GH pulse without raising cortisol, prolactin, or ACTH; half-life ~2 hours. Together: GHRH receptor activation + ghrelin receptor activation = synergistic GH pulse 3-5x larger than either alone.

The DAC Distinction

CJC-1295 WITH DAC (Drug Affinity Complex): half-life ~8 days; once-weekly dosing; produces sustained, non-pulsatile GH elevation; blunts natural GH pulsatility; may cause receptor desensitization. CJC-1295 WITHOUT DAC (Mod GRF 1-29): half-life ~30 minutes; clears between doses; preserves pulsatile GH release pattern; physiologically appropriate. For most community protocols: no DAC is preferred. DAC is never appropriate for the bedtime pulsatile protocol.

The Empty Stomach Rule

Food — especially carbohydrates — raises blood glucose and insulin, which directly suppresses GH release from the pituitary. Insulin and GH are counter-regulatory hormones. Injecting this stack within 1-2 hours of a carbohydrate-containing meal substantially blunts or eliminates the GH pulse. Wait 2+ hours after any significant meal. Do not eat for 20-30 minutes after injection. This rule is not optional and not community superstition — it has a clear physiological mechanism.

Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this class Compare 4 side by side →

CIT Stack

Same class · GH Secretagogue Stack

GH stack plus tesamorelin: a community combination built from GH-axis peptides with different regulatory identities, not a single FDA-approved product.

CJC-1295 (no-DAC)

Same class · GHRH Analog

The Most Common Community GHRH Analog — Sold Under Three Names. The DAC Confusion That Has Been Causing Purchasing Errors for a Decade. Why DAC Changes Everything About the Dosing Protocol. The Four Substitutions That Make Mod GRF 1-29 Last Long Enough to Work. How the GHRH Receptor and GHS-R1a Receptors Synergize. Why Teichman 2006 Actually Studied CJC-1295 WITH DAC — Not This Compound. The Empty Stomach Rule Is Not Optional.

CJC-1295 + Ipamorelin